Patent Expiry

Patent/Exclusivity Expiry: CARDAMYST

July 15, 2042

Company: Milestone Pharmaceuticals Inc. (MIST)
Drug: CARDAMYST

Other upcoming events for MIST

Phase 3 ReadoutPhase 3 Topline: Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients With Atria

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Patent/Exclusivity Expiry: CARDAMYST — MIST Patent Expiry | BioSniper